title: Prevalence of hemochromatosis among first-time and repeat blood donors in Norway.
abstract: OBJECTIVE
  The observed prevalence of hemochromatosis has ranged considerably from 0.05 to 0.37% in studies requiring liver biopsy. We aimed to study the prevalence of genetic hemochromatosis among Norwegian blood donors.
  
  
  METHODS
  We studied 10,552 healthy blood donors (5312 women and 5240 men) using serum ferritin as a screening parameter. If serum ferritin concentration was > or = 100 micrograms/l in women and > or = 200 micrograms/l in men, serum iron and transferrin (measured as total iron binding capacity = TIBC) were measured. Blood donors who repeatedly had a transferrin saturation above 40% and a ferritin concentration above these limits were referred to a hepatologist (H.B.).
  
  
  RESULTS
  Serum ferritin was > or = 100 micrograms/l in 94/5312 (1.8%) women and > or = 200 microliters in 79/5240 (1.5%) men. Of these, 37 persons had a serum ferritin concentration above 100 micrograms/l (females) or above 200 micrograms/l (males) and a transferrin saturation above 40%. Nineteen of them (13 men and 6 women, median age 36 years, range 28-68) were identified as having hemochromatosis on the basis of increased hepatic iron index. Serum ferritin ranged from 111 to 1980 micrograms/l (median 357 micrograms/l and transferrin saturation from 50 to 100% (median 92%), hepatic iron from 48 to 471 mumol/g dry weight (median 118 mumol/g) and hepatic iron index from 1.5 to 12.1 (median 3.0). One person had cirrhosis and none had diabetes. The prevalence of hemochromatosis was significantly higher among first-time blood donors (12 out of 3500 [3.4/1000]) compared with repeat donors (7 out of 7052 [1/1000]), p < 0.005.
  
  
  CONCLUSIONS
  The observed prevalence of hemochromatosis in Norwegian first-time blood donors of 0.34% is comparable to recently observed prevalences in other studies. However, the use of serum ferritin as a first-step screening tool may have failed to detect hemochromatosis in the early stage where iron overload has not yet occurred.
authors.affiliation: Department of Medicine, Aker University Hospital, Oslo, Norway.
authors.forename: H
authors.initials: H
authors.lastname: Bell
authors.forename: C
authors.initials: C
authors.lastname: Thordal
authors.forename: N
authors.initials: N
authors.lastname: Raknerud
authors.forename: T
authors.initials: T
authors.lastname: Hansen
authors.forename: V
authors.initials: V
authors.lastname: Bosnes
authors.forename: R
authors.initials: R
authors.lastname: Halvorsen
authors.forename: H E
authors.initials: HE
authors.lastname: Heier
authors.forename: K
authors.initials: K
authors.lastname: Try
authors.forename: T
authors.initials: T
authors.lastname: Leivestad
authors.forename: Y
authors.initials: Y
authors.lastname: Thomassen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001782:Blood Donors; D001788:Blood Grouping and Crossmatching; D005260:Female; D005293:Ferritins / Q000097:blood; D006432:Hemochromatosis / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009664:Norway / Q000453:epidemiology; D015995:Prevalence; D014168:Transferrin / Q000378:metabolism
chemical_list: D014168:Transferrin; D005293:Ferritins